{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:08:06Z","timestamp":1793840886245,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-018460"],"award-info":[{"award-number":["INV-018460"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221988\/Z\/20\/Z"],"award-info":[{"award-number":["221988\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T16:21:23Z","timestamp":1678897283000},"page":"2634-2644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-7880","authenticated-orcid":false,"given":"Mark S.","family":"Riddle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Louis Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhi","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte K.","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tufet Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Ovitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Hausdorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.003_b0005","first-page":"18","article-title":"Estimates of the Global, Regional, and National Morbidity, Mortality, and Aetiologies of Diarrhoea in 195 Countries: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"2018","author":"Troeger","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.003_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(19)30541-8","article-title":"Diarrhoeal Disease and Subsequent Risk of Death in Infants and Children Residing in Low-Income and Middle-Income Countries: Analysis of the GEMS Case-Control Study and 12-Month GEMS-1A Follow-on Study","volume":"8","author":"Levine","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.003_b0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","article-title":"The Role of Vaccines in Combatting Antimicrobial Resistance","volume":"19","author":"Micoli","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2023.03.003_b0020","first-page":"399","article-title":"A Systematic Analysis","volume":"2022","author":"Murray","year":"2019","journal-title":"Lancet"},{"issue":"10325","key":"10.1016\/j.vaccine.2023.03.003_b0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(22)00087-3","article-title":"The Overlooked Pandemic of Antimicrobial Resistance","volume":"399","author":"Laxminarayan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.03.003_b0030","first-page":"1","article-title":"From Kiyoshi Shiga to Present-Day Shigella Vaccines: A Historical Narrative Review","volume":"10","author":"Herrera","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.03.003_b0035","unstructured":"WHO. WHO Preferred Product Characteristics for Vaccines against Shigella.; Geneva, 2021; https:\/\/www.who.int\/publications\/i\/item\/9789240036741."},{"key":"10.1016\/j.vaccine.2023.03.003_b0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/vaccines10020282","article-title":"What Drives the Value of a Shigella Vaccine?","volume":"10","author":"Hausdorff","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.03.003_b0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0264-410X(02)00461-9","article-title":"Comparative Evaluation of a Combined DTP-HB Vaccine in the EPI in Chiangrai Province, Thailand","volume":"21","author":"Chunsuttiwat","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.003_b0050","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2214-109X(19)30541-8","article-title":"Diarrhoeal Disease and Subsequent Risk of Death in Infants and Children Residing in Low-Income and Middle-Income Countries: Analysis of the GEMS Case-Control Study and 12-Month GEMS-1A Follow-on Study","volume":"8","author":"Levine","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.03.003_b0055","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/S2214-109X(15)00151-5","article-title":"Pathogen-Specific Burdens of Community Diarrhoea in Developing Countries: A Multisite Birth Cohort Study (MAL-ED)","volume":"3","author":"Platts-Mills","year":"2015","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.03.003_b0060","doi-asserted-by":"crossref","first-page":"e1319","DOI":"10.1016\/S2214-109X(18)30351-6","article-title":"Use of Quantitative Molecular Diagnostic Methods to Investigate the Effect of Enteropathogen Infections on Linear Growth in Children in Low-Resource Settings: Longitudinal Analysis of Results from the MAL-ED Cohort Study","volume":"6","author":"Rogawski","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.03.003_b0065","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3201\/eid1611.090934","article-title":"Decrease in Shigellosis-Related Deaths without Shigella Spp.-Specific Interventions","volume":"16","author":"Bardhan","year":"2010","journal-title":"Asia. Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.003_b0070","doi-asserted-by":"crossref","first-page":"S848","DOI":"10.1093\/infdis\/jiab434","article-title":"Pathogens Associated With Linear Growth Faltering in Children With Diarrhea and Impact of Antibiotic Treatment: The Global Enteric Multicenter Study","volume":"224","author":"Nasrin","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.003_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9071382","article-title":"Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease","volume":"9","author":"Walker","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2023.03.003_b0080","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/acsinfecdis.0c00831","article-title":"Modeling Enteropathy or Diarrhea with the Top Bacterial and Protozoal Pathogens: Differential Determinants of Outcomes","volume":"7","author":"Guerrant","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.003_b0085","unstructured":"FDA Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies; Rockville, MD, 1997; https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-evaluation-combination-vaccines-preventable-diseases-production-testing-and."},{"key":"10.1016\/j.vaccine.2023.03.003_b0090","unstructured":"EMA Note for Guidance on Pharmaceutical and Biological Aspects of Combined Vaccine ; London, UK, 1998; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-pharmaceutical-biological-aspects-combined-vaccines_en.pdf."},{"key":"10.1016\/j.vaccine.2023.03.003_b0095","unstructured":"EMA Guideline on Clinical Evaluation of New Vaccines; London, UK, 2007; https:\/\/www.ema.europa.eu\/en\/clinical-evaluation-new-vaccines."},{"key":"10.1016\/j.vaccine.2023.03.003_b0100","doi-asserted-by":"crossref","unstructured":"Camp Jv, Wilson RL, Singletary M, Blanchard JL, Aldovini, A, Kaminski RW, et al. Invaplex Functions as an Intranasal Adjuvant for Subunit and DNA Vaccines Co-Delivered in the Nasal Cavity of Nonhuman Primates. Vaccine X 2021; 8: 100105, doi:10.1016\/j.jvacx.2021.100105.","DOI":"10.1016\/j.jvacx.2021.100105"},{"key":"10.1016\/j.vaccine.2023.03.003_b0105","unstructured":"CDC; ACIP Update: Recommendations from the Advisory Committee on Immunization Practices (ACIP) Regarding Administration of Combination MMRV Vaccine. MMWR Morb Mortal Wkly Rep 2008, 57, 258\u2013260; https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5710a3.htm."},{"key":"10.1016\/j.vaccine.2023.03.003_b0110","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jama.1992.03480050077028","article-title":"Impact of Haemophilus Influenzae Type b Polysaccharide-Tetanus Protein Conjugate Vaccine on Responses to Concurrently Administered Diphtheria-Tetanus-Pertussis Vaccine","volume":"267","author":"Clemens","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.03.003_b0115","unstructured":"WHO Recommendations to Assure the Quality, Safety and Efficacy of Pneumococcal Conjugate Vaccines, Annex 3, TRS No 977; Geneva, Switzerland, 2013; https:\/\/www.who.int\/publications\/m\/item\/pneumococcal-conjugate-vaccines-annex3-trs-977."},{"key":"10.1016\/j.vaccine.2023.03.003_b0120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged \u226518 Years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.003_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100024","article-title":"Potential Impact and Cost-Effectiveness of Future ETEC and Shigella Vaccines in 79 Low- and Lower Middle-Income Countries","volume":"2","author":"Anderson","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2023.03.003_b0130","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3841999","article-title":"The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making","author":"Hutubessy","year":"2021","journal-title":"SSRN Electron J"},{"key":"10.1016\/j.vaccine.2023.03.003_b0135","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2012.03.022","article-title":"Parental and Societal Values for the Risks and Benefits of Childhood Combination Vaccines","volume":"30","author":"Gidengil","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.003_b0140","doi-asserted-by":"crossref","unstructured":"WHO (World Health Organization) Measles Vaccines: WHO Position Paper, April 2017 - Recommendations. Vaccine 2019, 37, 219\u2013222, doi:10.1016\/j.vaccine.2017.07.066.","DOI":"10.1016\/j.vaccine.2017.07.066"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:24Z","timestamp":1759404264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002505"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}